Scientists from the Swiss antibody company Humabs BioMed SA have characterised the human immune response to infection from the Zika virus and shown for the first time that antibodies derived from infected patients may not only be useful for developing diagnostics and therapies, but also answer the question of why Zika infections can become more dangerous if a person is infected with Dengue fever later in life.
